| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy Complications, Infectious | 14 | 2026 | 158 | 5.330 |
Why?
|
| Vaccination | 28 | 2026 | 725 | 4.980 |
Why?
|
| Influenza, Human | 14 | 2026 | 292 | 4.510 |
Why?
|
| Influenza Vaccines | 15 | 2026 | 300 | 4.270 |
Why?
|
| Autism Spectrum Disorder | 11 | 2022 | 165 | 3.020 |
Why?
|
| Vaccination Coverage | 8 | 2026 | 68 | 2.590 |
Why?
|
| Pregnancy | 32 | 2026 | 1555 | 2.550 |
Why?
|
| Whooping Cough | 6 | 2026 | 71 | 2.100 |
Why?
|
| Humans | 85 | 2026 | 16832 | 2.040 |
Why?
|
| Infant | 23 | 2026 | 1212 | 2.040 |
Why?
|
| Female | 67 | 2026 | 12193 | 1.950 |
Why?
|
| Vaccines | 5 | 2025 | 225 | 1.850 |
Why?
|
| Young Adult | 33 | 2026 | 2456 | 1.690 |
Why?
|
| California | 28 | 2026 | 2244 | 1.690 |
Why?
|
| Adult | 50 | 2026 | 7255 | 1.680 |
Why?
|
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 5 | 2026 | 98 | 1.580 |
Why?
|
| Autistic Disorder | 5 | 2017 | 117 | 1.560 |
Why?
|
| Measles | 3 | 2022 | 25 | 1.440 |
Why?
|
| Measles-Mumps-Rubella Vaccine | 4 | 2022 | 64 | 1.400 |
Why?
|
| Male | 42 | 2026 | 9556 | 1.340 |
Why?
|
| Immunization Schedule | 5 | 2021 | 127 | 1.220 |
Why?
|
| Child | 19 | 2026 | 2433 | 1.210 |
Why?
|
| Infant, Newborn | 14 | 2026 | 828 | 1.180 |
Why?
|
| Hospitalization | 12 | 2026 | 816 | 1.120 |
Why?
|
| Adolescent | 27 | 2026 | 3464 | 1.120 |
Why?
|
| Pregnancy Outcome | 4 | 2025 | 160 | 0.910 |
Why?
|
| Case-Control Studies | 17 | 2023 | 995 | 0.900 |
Why?
|
| Child, Preschool | 13 | 2025 | 1430 | 0.870 |
Why?
|
| Retrospective Studies | 22 | 2026 | 2463 | 0.830 |
Why?
|
| Cohort Studies | 13 | 2026 | 2396 | 0.820 |
Why?
|
| Mumps | 2 | 2020 | 13 | 0.790 |
Why?
|
| Mothers | 3 | 2023 | 104 | 0.760 |
Why?
|
| United States | 19 | 2026 | 3858 | 0.730 |
Why?
|
| Prenatal Care | 2 | 2020 | 123 | 0.700 |
Why?
|
| Seizures, Febrile | 1 | 2022 | 42 | 0.700 |
Why?
|
| Immunologic Factors | 1 | 2022 | 35 | 0.690 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2015 | 206 | 0.690 |
Why?
|
| Fever | 3 | 2022 | 52 | 0.690 |
Why?
|
| Vaccines, Combined | 7 | 2023 | 80 | 0.650 |
Why?
|
| Databases, Factual | 2 | 2025 | 294 | 0.640 |
Why?
|
| Child Development Disorders, Pervasive | 3 | 2017 | 31 | 0.630 |
Why?
|
| Risk Factors | 11 | 2024 | 3108 | 0.610 |
Why?
|
| Middle Aged | 25 | 2026 | 7515 | 0.600 |
Why?
|
| Insurance, Health | 2 | 2021 | 167 | 0.590 |
Why?
|
| Breast Neoplasms | 6 | 2016 | 913 | 0.590 |
Why?
|
| Early Diagnosis | 2 | 2019 | 33 | 0.560 |
Why?
|
| Cytokines | 2 | 2019 | 28 | 0.560 |
Why?
|
| Antigens | 1 | 2018 | 7 | 0.540 |
Why?
|
| Infection | 1 | 2018 | 17 | 0.540 |
Why?
|
| Pregnancy Trimester, First | 1 | 2017 | 45 | 0.500 |
Why?
|
| Chickenpox Vaccine | 4 | 2022 | 91 | 0.500 |
Why?
|
| Delivery of Health Care | 3 | 2022 | 374 | 0.490 |
Why?
|
| Developmental Disabilities | 3 | 2019 | 53 | 0.490 |
Why?
|
| Antiviral Agents | 3 | 2026 | 92 | 0.490 |
Why?
|
| Seasons | 4 | 2025 | 114 | 0.480 |
Why?
|
| C-Reactive Protein | 1 | 2016 | 52 | 0.470 |
Why?
|
| Incidence | 8 | 2024 | 1229 | 0.460 |
Why?
|
| Birth Intervals | 1 | 2015 | 7 | 0.460 |
Why?
|
| Respiratory Syncytial Virus Infections | 2 | 2026 | 40 | 0.450 |
Why?
|
| Clinical Competence | 1 | 2015 | 107 | 0.440 |
Why?
|
| Hypersensitivity | 1 | 2015 | 20 | 0.440 |
Why?
|
| Autoimmune Diseases | 1 | 2015 | 19 | 0.430 |
Why?
|
| Physicians | 1 | 2015 | 114 | 0.420 |
Why?
|
| Odds Ratio | 5 | 2023 | 569 | 0.420 |
Why?
|
| Premature Birth | 5 | 2024 | 133 | 0.400 |
Why?
|
| Aged | 17 | 2026 | 5901 | 0.400 |
Why?
|
| Vaccines, Inactivated | 4 | 2026 | 73 | 0.400 |
Why?
|
| Logistic Models | 5 | 2020 | 796 | 0.380 |
Why?
|
| Immunocompromised Host | 2 | 2021 | 16 | 0.360 |
Why?
|
| Risk Assessment | 6 | 2022 | 1047 | 0.360 |
Why?
|
| Emergency Service, Hospital | 6 | 2025 | 393 | 0.360 |
Why?
|
| Infant, Small for Gestational Age | 3 | 2024 | 55 | 0.350 |
Why?
|
| Surveys and Questionnaires | 1 | 2015 | 1204 | 0.350 |
Why?
|
| Asthma | 1 | 2015 | 375 | 0.350 |
Why?
|
| Fertilization | 1 | 2011 | 3 | 0.340 |
Why?
|
| Vaccines, Attenuated | 2 | 2022 | 44 | 0.340 |
Why?
|
| Risk | 5 | 2016 | 453 | 0.330 |
Why?
|
| Proportional Hazards Models | 5 | 2026 | 657 | 0.300 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 1058 | 0.290 |
Why?
|
| Central Nervous System Stimulants | 2 | 2011 | 23 | 0.280 |
Why?
|
| Pregnant Women | 2 | 2021 | 41 | 0.280 |
Why?
|
| Aged, 80 and over | 9 | 2026 | 1887 | 0.280 |
Why?
|
| RNA, Messenger | 6 | 2023 | 66 | 0.280 |
Why?
|
| Respiratory Syncytial Virus Vaccines | 1 | 2026 | 12 | 0.240 |
Why?
|
| Adjuvants, Immunologic | 1 | 2026 | 19 | 0.240 |
Why?
|
| Breast Density | 1 | 2016 | 24 | 0.240 |
Why?
|
| Ambulatory Care | 3 | 2022 | 205 | 0.240 |
Why?
|
| Time Factors | 4 | 2022 | 989 | 0.230 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2025 | 23 | 0.220 |
Why?
|
| Immunization | 1 | 2025 | 70 | 0.210 |
Why?
|
| Insulin, Long-Acting | 1 | 2013 | 10 | 0.200 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2024 | 353 | 0.200 |
Why?
|
| Cluster Analysis | 1 | 2023 | 88 | 0.190 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 2 | 2011 | 64 | 0.190 |
Why?
|
| Mucocutaneous Lymph Node Syndrome | 1 | 2022 | 18 | 0.190 |
Why?
|
| Pneumococcal Infections | 1 | 2022 | 43 | 0.180 |
Why?
|
| Herpesvirus 3, Human | 1 | 2012 | 40 | 0.180 |
Why?
|
| Rotavirus Vaccines | 1 | 2022 | 53 | 0.180 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2013 | 116 | 0.180 |
Why?
|
| Tetanus | 2 | 2026 | 23 | 0.180 |
Why?
|
| Pericarditis | 1 | 2022 | 11 | 0.180 |
Why?
|
| Myocarditis | 1 | 2022 | 14 | 0.180 |
Why?
|
| Cataplexy | 1 | 2022 | 6 | 0.180 |
Why?
|
| Narcolepsy | 1 | 2022 | 8 | 0.180 |
Why?
|
| Pneumococcal Vaccines | 1 | 2022 | 67 | 0.180 |
Why?
|
| Bell Palsy | 1 | 2022 | 14 | 0.180 |
Why?
|
| Measles Vaccine | 1 | 2022 | 17 | 0.180 |
Why?
|
| Thrombocytopenia | 1 | 2022 | 17 | 0.180 |
Why?
|
| Vaccines, Synthetic | 4 | 2022 | 39 | 0.180 |
Why?
|
| Prostatic Neoplasms | 1 | 2013 | 196 | 0.180 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 104 | 0.170 |
Why?
|
| Infant, Premature | 1 | 2022 | 59 | 0.170 |
Why?
|
| Herpes Zoster | 1 | 2012 | 80 | 0.170 |
Why?
|
| Rubella | 1 | 2020 | 6 | 0.160 |
Why?
|
| Spatial Analysis | 1 | 2020 | 11 | 0.160 |
Why?
|
| Geography | 1 | 2020 | 39 | 0.160 |
Why?
|
| Pandemics | 4 | 2024 | 289 | 0.160 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 1 | 2010 | 30 | 0.160 |
Why?
|
| Bursitis | 1 | 2020 | 4 | 0.160 |
Why?
|
| Shoulder Joint | 1 | 2020 | 6 | 0.160 |
Why?
|
| Telemedicine | 1 | 2024 | 190 | 0.160 |
Why?
|
| Neoplasms, Second Primary | 1 | 2010 | 29 | 0.160 |
Why?
|
| Eggs | 1 | 2020 | 8 | 0.160 |
Why?
|
| Pregnancy Trimester, Second | 2 | 2019 | 29 | 0.160 |
Why?
|
| Influenza A virus | 1 | 2020 | 13 | 0.160 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 36 | 0.160 |
Why?
|
| Communicable Diseases | 1 | 2020 | 14 | 0.150 |
Why?
|
| Comorbidity | 3 | 2019 | 516 | 0.150 |
Why?
|
| Carcinoma in Situ | 1 | 2009 | 12 | 0.150 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2009 | 42 | 0.150 |
Why?
|
| Chemokines | 1 | 2019 | 5 | 0.150 |
Why?
|
| Child Development | 1 | 2020 | 58 | 0.150 |
Why?
|
| Hispanic Americans | 1 | 2020 | 350 | 0.140 |
Why?
|
| Residence Characteristics | 1 | 2020 | 244 | 0.140 |
Why?
|
| Croup | 1 | 2018 | 4 | 0.140 |
Why?
|
| Otitis Media | 1 | 2018 | 19 | 0.140 |
Why?
|
| African Americans | 1 | 2020 | 394 | 0.140 |
Why?
|
| Gastrointestinal Diseases | 1 | 2018 | 26 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2009 | 222 | 0.130 |
Why?
|
| Neoplasms | 1 | 2012 | 447 | 0.130 |
Why?
|
| Breast Diseases | 1 | 2007 | 11 | 0.130 |
Why?
|
| Body Constitution | 1 | 2007 | 35 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2018 | 58 | 0.130 |
Why?
|
| Prevalence | 2 | 2022 | 785 | 0.130 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 635 | 0.130 |
Why?
|
| Infant, Low Birth Weight | 1 | 2017 | 30 | 0.130 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 677 | 0.130 |
Why?
|
| Proof of Concept Study | 1 | 2016 | 3 | 0.120 |
Why?
|
| Pregnancy Complications | 1 | 2019 | 202 | 0.120 |
Why?
|
| Gestational Age | 1 | 2017 | 118 | 0.120 |
Why?
|
| Pertussis Vaccine | 1 | 2016 | 13 | 0.120 |
Why?
|
| Pesticides | 1 | 2016 | 8 | 0.120 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2016 | 6 | 0.120 |
Why?
|
| Cardiovascular Diseases | 1 | 2011 | 520 | 0.120 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2016 | 11 | 0.120 |
Why?
|
| Diphtheria | 1 | 2016 | 13 | 0.120 |
Why?
|
| Mammography | 3 | 2016 | 141 | 0.120 |
Why?
|
| Women's Health | 1 | 2007 | 178 | 0.120 |
Why?
|
| Prospective Studies | 2 | 2020 | 1186 | 0.120 |
Why?
|
| Intellectual Disability | 1 | 2016 | 22 | 0.120 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 27 | 0.120 |
Why?
|
| Drug Utilization Review | 1 | 2006 | 21 | 0.120 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2006 | 10 | 0.120 |
Why?
|
| Raloxifene Hydrochloride | 1 | 2006 | 11 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2006 | 40 | 0.120 |
Why?
|
| Postpartum Period | 1 | 2016 | 89 | 0.120 |
Why?
|
| Maternal Exposure | 1 | 2016 | 84 | 0.110 |
Why?
|
| Environmental Pollutants | 1 | 2016 | 68 | 0.110 |
Why?
|
| State Health Plans | 1 | 2005 | 30 | 0.110 |
Why?
|
| Age Distribution | 3 | 2012 | 221 | 0.100 |
Why?
|
| Prognosis | 3 | 2020 | 568 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2006 | 290 | 0.100 |
Why?
|
| Antipyretics | 1 | 2013 | 4 | 0.100 |
Why?
|
| Genome-Wide Association Study | 1 | 2013 | 209 | 0.090 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 305 | 0.090 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 319 | 0.090 |
Why?
|
| Immunization, Secondary | 2 | 2022 | 58 | 0.090 |
Why?
|
| Laboratories | 2 | 2021 | 17 | 0.090 |
Why?
|
| European Continental Ancestry Group | 2 | 2016 | 400 | 0.080 |
Why?
|
| Age Factors | 2 | 2025 | 814 | 0.080 |
Why?
|
| Multivariate Analysis | 1 | 2011 | 489 | 0.080 |
Why?
|
| Treatment Outcome | 2 | 2025 | 1098 | 0.070 |
Why?
|
| Early Detection of Cancer | 2 | 2016 | 553 | 0.070 |
Why?
|
| Tamoxifen | 2 | 2009 | 52 | 0.070 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2009 | 56 | 0.070 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2026 | 29 | 0.060 |
Why?
|
| Cross-Over Studies | 1 | 2026 | 47 | 0.060 |
Why?
|
| SEER Program | 1 | 2016 | 86 | 0.060 |
Why?
|
| Delivery of Health Care, Integrated | 2 | 2021 | 515 | 0.060 |
Why?
|
| Insulin Glargine | 1 | 2013 | 6 | 0.050 |
Why?
|
| Hematologic Neoplasms | 1 | 2012 | 8 | 0.050 |
Why?
|
| RNA, Messenger, Stored | 1 | 2022 | 3 | 0.050 |
Why?
|
| Reference Values | 1 | 2012 | 78 | 0.050 |
Why?
|
| Vaccines, Conjugate | 1 | 2022 | 59 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2012 | 164 | 0.050 |
Why?
|
| Recurrence | 1 | 2012 | 149 | 0.050 |
Why?
|
| Mental Disorders | 2 | 2015 | 248 | 0.050 |
Why?
|
| Hospital Mortality | 1 | 2023 | 134 | 0.050 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2011 | 27 | 0.040 |
Why?
|
| Patient Safety | 1 | 2022 | 37 | 0.040 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 96 | 0.040 |
Why?
|
| Hypoglycemic Agents | 1 | 2013 | 247 | 0.040 |
Why?
|
| Anxiety | 1 | 2022 | 154 | 0.040 |
Why?
|
| Stress, Psychological | 1 | 2022 | 136 | 0.040 |
Why?
|
| Deltoid Muscle | 1 | 2020 | 4 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2020 | 9 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 70 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 36 | 0.040 |
Why?
|
| Public Health Surveillance | 1 | 2020 | 42 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2009 | 12 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2021 | 145 | 0.040 |
Why?
|
| Myocardial Infarction | 1 | 2011 | 215 | 0.040 |
Why?
|
| Continental Population Groups | 1 | 2021 | 255 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2009 | 79 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 325 | 0.040 |
Why?
|
| Stroke | 1 | 2011 | 297 | 0.040 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 1233 | 0.030 |
Why?
|
| Ethnic Groups | 1 | 2021 | 418 | 0.030 |
Why?
|
| Biomarkers | 1 | 2019 | 284 | 0.030 |
Why?
|
| Depression | 1 | 2022 | 479 | 0.030 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2007 | 69 | 0.030 |
Why?
|
| African Continental Ancestry Group | 1 | 2007 | 117 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2011 | 702 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 21 | 0.030 |
Why?
|
| Receptors, Estrogen | 1 | 2006 | 46 | 0.030 |
Why?
|
| Bone Density | 1 | 2006 | 93 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2006 | 322 | 0.030 |
Why?
|
| Health Maintenance Organizations | 1 | 2006 | 358 | 0.030 |
Why?
|
| Registries | 1 | 2006 | 449 | 0.030 |
Why?
|
| Databases, Genetic | 1 | 2013 | 8 | 0.030 |
Why?
|
| Mother-Child Relations | 1 | 2013 | 13 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2013 | 21 | 0.030 |
Why?
|
| Phenotype | 1 | 2013 | 105 | 0.020 |
Why?
|
| Genotype | 1 | 2013 | 198 | 0.020 |
Why?
|
| Sex Factors | 1 | 2015 | 560 | 0.020 |
Why?
|
| Health Status | 1 | 2015 | 256 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2007 | 925 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2015 | 382 | 0.020 |
Why?
|
| Orbital Neoplasms | 1 | 1970 | 1 | 0.010 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1970 | 26 | 0.000 |
Why?
|
| Cobalt Isotopes | 1 | 1970 | 1 | 0.000 |
Why?
|
| Eye Manifestations | 1 | 1970 | 1 | 0.000 |
Why?
|
| Eye Diseases | 1 | 1970 | 5 | 0.000 |
Why?
|